Date of Abstract presentation10th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number602Abstract typeOral
In the TRANSCEND FL study, 130 individuals grappling with relapsed or refractory follicular lymphoma (FL) were actively involved and subjected to BREYANZI treatment within the second-line and third-line settings. These patients were administered BREYANZI at a targeted dosage of 100 x 106 CAR-positive viable T cells. Remarkably, TRANSCEND FL stands as the largest clinical trial assessing the efficacy of CAR T cell therapy in individuals with relapsed or refractory FL. Moreover, it marks the pioneering trial to divulge outcomes for a CAR T therapy in ...
